LL37: Revolutionizing Antimicrobial Therapy for Infections, Wound Healing, and Immunity
A short clinician-style training talk in which Dr. Adam Sewell outlines what he says LL-37 does, how he describes dosing and monitoring it, and three illustrative cases.
With Dr. Adam Sewell (MD)
Key moments
Tap a moment to play the video from there.
- 0:00Introduction to LL-37Sewell frames the session as training on LL-37, a human-derived antimicrobial peptide. He says it is not FDA approved and is widely studied for resistant infections, inflammation and wound healing.
- 1:17Four claimed mechanisms of actionHe describes membrane disruption of microbes, immune regulation, wound repair through new blood vessel growth and collagen, and breakdown of biofilms.
- 2:21Clinical areas of interestSewell lists resistant infections including MRSA, chronic wounds, inflammatory conditions, respiratory viruses, cancer research and biofilm-related infections.
- 3:20Benefits, risks and alternativesHe names broad antimicrobial activity and tissue repair as potential benefits. The risks he names are injection site reactions, brief flu-like symptoms, possible immune overactivation and limited long-term data. He also lists conventional alternatives.
- 4:55Dosage protocols as presentedSewell gives 50 to 100 micrograms per kilogram for infections and wounds, and 100 micrograms per kilogram for inflammatory conditions. He says courses usually run 2 to 8 weeks.
- 5:43Lab testing and monitoringHe recommends baseline blood counts, a metabolic panel, CRP and ESR, and cultures. Inflammatory markers and wound assessments follow during treatment, and repeat cultures come afterward.
- 6:31Case studies: wound and sinusSewell describes a 65-year-old with a diabetic foot ulcer and a 40-year-old with recurrent MRSA sinusitis. He reports healing in the first case and clearance of MRSA on culture in the second.
- 7:43Case study: ulcerative colitisHe describes a 32-year-old with ulcerative colitis whose markers and symptoms improved, with remission reported by week eight.
- 8:02Conclusion and certification pitchSewell calls LL-37 a promising adjunct for refractory problems while repeating that it is a research compound. He ends by promoting a free peptide therapy course.
What the video says
Dr. Adam Sewell presents an 8-minute training session on LL-37, which he describes as a human-derived antimicrobial peptide taken from cathelicidin. He says it is made by epithelial cells, immune cells and keratinocytes, and that it is the only human cathelicidin identified so far. He states clearly that it is not FDA approved and that it remains a research compound.
Sewell lists four mechanisms: disrupting microbial membranes, regulating immune responses, stimulating tissue repair, and breaking down biofilms. He then goes through the areas where he says it shows promise. These include resistant infections such as MRSA, chronic wounds, inflammatory and autoimmune conditions, respiratory viral infections, cancer research and biofilm-related infections. He lists benefits, then risks. The risks he names are injection site reactions, brief flu-like symptoms, a theoretical chance of immune overactivation and limited long-term safety data. He also names conventional alternatives for each goal.
The dosing section gives Sewell's figures. For chronic infections and wound healing he cites 50 to 100 micrograms per kilogram, given under the skin daily or every other day. For autoimmune or inflammatory conditions he cites 100 micrograms per kilogram, two to three times per week. He says courses typically run 2 to 8 weeks and may be repeated. He recommends baseline blood counts, a metabolic panel, inflammatory markers and cultures, with repeat testing during and after treatment.
The last third covers three case studies that Sewell describes: a diabetic foot ulcer, an MRSA sinus infection and ulcerative colitis. In each he reports a favorable outcome. They are presented as illustrations, with no data, controls or sources shown. The video closes with a pitch for the creator's free peptide therapy certification course.
On each compound
LL-370:30
Sewell describes LL-37 as a human antimicrobial peptide with antimicrobial, anti-inflammatory, wound-healing and biofilm-disrupting effects. He says it is not FDA approved and still a research compound. He cites doses of 50 to 100 micrograms per kilogram under the skin and reports favorable results in three illustrative cases.
See how your DNA reads LL-37“while not FDA approved ll37 is widely studied”
What this video doesn’t settle
- The three case studies are single patients described by the presenter, with no data shown, no control group and no source given.
- The video does not cite trials or published studies for its dosing figures or its claims about efficacy.
- Sewell calls LL-37 generally well tolerated but also says long-term safety data are limited, and the video does not resolve that gap.
Questions this video answers
What does Dr. Sewell say LL-37 does?
Sewell says LL-37 disrupts microbial membranes, modulates immune responses, supports tissue repair and breaks down biofilms. He presents these as the basis for its use in infections, inflammation and slow-healing wounds.
Is LL-37 FDA approved according to this video?
No. Sewell says plainly that LL-37 is not FDA approved and calls it a research compound with limited long-term safety data.
What LL-37 doses does Sewell mention?
He cites 50 to 100 micrograms per kilogram for chronic infections and wound healing, and 100 micrograms per kilogram for autoimmune or inflammatory conditions. He gives these as typical protocols lasting 2 to 8 weeks. They are his figures, not advice.
What side effects of LL-37 does the video mention?
Sewell says it is generally well tolerated. The risks he lists are injection site redness, swelling or discomfort, brief flu-like symptoms such as mild fatigue or fever, and a theoretical risk of immune overactivation.
What lab tests does Sewell suggest when using LL-37?
He lists baseline blood counts, a metabolic panel, CRP, ESR and cultures for infections. He then recommends tracking inflammatory markers and wound metrics during treatment, and repeating cultures afterward.
Video by Dr. Adam Sewell, M.D. | Medical Entrepreneur on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
